Drug Approval | November 02, 2023
NATCO Pharma announces successful completion of USFDA inspection
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
Investment is additive to KKR’s existing health care growth strategy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
New Board of Directors and management team at Suven Pharma also appointed
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Subscribe To Our Newsletter & Stay Updated
